- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03436719
Antibiotic Prophylaxis in Rectal Cancer Surgery: Oral With Intravenous Versus Intravenous Antibiotics.
March 4, 2019 updated by: Rybakov Evgeny, MD, State Scientific Centre of Coloproctology, Russian Federation
Randomized Controlled Trial of Antibiotic Prophylaxis in Rectal Cancer Surgery: Oral With Intravenous Versus Intravenous Antibiotics.
This is a randomized, controlled, parallel study to determine the efficiency of oral antibiotics in reduction of surgical site infection (SSI) in rectal cancer surgery.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Patients undergoing rectal cancer surgery in a single centre will assigned randomly to combined preoperative oral antibiotics (metronidazole and erythromycin) and perioperative intravenous antibiotics (cefmetazole) (oral+intravenous group) or to perioperative intravenous antibiotics (cefmetazole) alone (intravenous group).
The primary endpoint is the overall rate of SSI.
Study Type
Interventional
Enrollment (Anticipated)
280
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Moscow, Russian Federation, 123423
- Recruiting
- State Scientific Centre of Coloproctology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Have a planned of resection of rectum
- Have signed approved informed consent form for the study.
Exclusion Criteria:
- Significant simultaneous surgical procedure (e.g., liver resection of metastasis)
- Bacterial infection at the time of surgery or antimicrobial therapy up to 4 weeks before surgery
- Preoperative severe impairment in renal function (creatinine clearance (MDRD) < 30 ml/min)
- Allergy on the study drugs .
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Oral with Intravenous
Oral metronidazole and erythromycine administration on the day before surgery with intravenous cefoperazone before surgery (30-90 min) and additional doses every third hour during surgery
|
Metronidazole - 500 mg and Erythromycin - 500 mg per os *3 times at 5 p.m.; 8 p.m., 11 p.m. in a day before surgery
Other Names:
Cefoperazone - 1000 mg intravenously for 30-90 minutes before surgery
Other Names:
Beginning of MBP at 4 p.m. in a day before surgery
Other Names:
|
|
ACTIVE_COMPARATOR: Intravenous
Intravenous dose cefoperazone before surgery (30-90 min) and additional doses every third hour during surgery
|
Cefoperazone - 1000 mg intravenously for 30-90 minutes before surgery
Other Names:
Beginning of MBP at 4 p.m. in a day before surgery
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Rate of Surgical Site Infection
Time Frame: 0 to 30 days
|
0 to 30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
November 6, 2017
Primary Completion (ANTICIPATED)
July 31, 2020
Study Completion (ANTICIPATED)
August 31, 2020
Study Registration Dates
First Submitted
February 5, 2018
First Submitted That Met QC Criteria
February 10, 2018
First Posted (ACTUAL)
February 19, 2018
Study Record Updates
Last Update Posted (ACTUAL)
March 5, 2019
Last Update Submitted That Met QC Criteria
March 4, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Rectal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Gastrointestinal Agents
- Protein Synthesis Inhibitors
- Antiprotozoal Agents
- Antiparasitic Agents
- Antitubercular Agents
- Metronidazole
- Erythromycin
- Anti-Bacterial Agents
- Antibiotics, Antitubercular
- Cefoperazone
Other Study ID Numbers
- 76
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.